{"denoms":[{"counts":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"8"},{"groupId":"BG005","value":"50"}],"units":"Participants"}],"groups":[{"description":"Participants with normal renal function (RF; defined as 24-hour urine creatinine clearance (CrCL) \\> 80 mL/minute) received carfilzomib, 15 mg/m², administered intravenously (IV) on Days 1, 2, 8, 9, 15, and 16 of repeated 28-day cycles for a maximum of 12 cycles.\n\nIf the 15 mg/m² dose was tolerated the dose could be increased to 20 mg/m² starting at Cycle 2. If 20 mg/m² was tolerated, an additional dose escalation to 27 mg/m² was allowed at Cycle 3 or at subsequent cycles.","id":"BG000","title":"Carfilzomib - Normal RF"},{"description":"Participants with mild renal impairment (RI; CrCL between 50-80 mL/minute) received carfilzomib, 15 mg/m², administered intravenously on Days 1, 2, 8, 9, 15, and 16 of repeated 28-day cycles for a maximum of 12 cycles.\n\nIf the 15 mg/m² dose was tolerated the dose could be increased to 20 mg/m² starting at Cycle 2. If 20 mg/m² was tolerated, an additional dose escalation to 27 mg/m² was allowed at Cycle 3 or at subsequent cycles.","id":"BG001","title":"Carfilzomib - Mild RI"},{"description":"Participants with moderate renal impairment (CrCL between 30-49 mL/minute) received carfilzomib, 15 mg/m², administered intravenously on Days 1, 2, 8, 9, 15, and 16 of repeated 28-day cycles for a maximum of 12 cycles.\n\nIf the 15 mg/m² dose was tolerated the dose could be increased to 20 mg/m² starting at Cycle 2. If 20 mg/m² was tolerated, an additional dose escalation to 27 mg/m² was allowed at Cycle 3 or at subsequent cycles.","id":"BG002","title":"Carfilzomib - Moderate RI"},{"description":"Participants with severe renal impairment (CrCL \\< 30 mL/minute) received carfilzomib, 15 mg/m², administered intravenously on Days 1, 2, 8, 9, 15, and 16 of repeated 28-day cycles for a maximum of 12 cycles.\n\nIf the 15 mg/m² dose was tolerated the dose could be increased to 20 mg/m² starting at Cycle 2. If 20 mg/m² was tolerated, an additional dose escalation to 27 mg/m² was allowed at Cycle 3 or at subsequent cycles.","id":"BG003","title":"Carfilzomib - Severe RI"},{"description":"Participants undergoing chronic hemodialysis received carfilzomib, 15 mg/m², administered intravenously on Days 1, 2, 8, 9, 15, and 16 of repeated 28-day cycles for a maximum of 12 cycles.\n\nIf the 15 mg/m² dose was tolerated the dose could be increased to 20 mg/m² starting at Cycle 2. If 20 mg/m² was tolerated, an additional dose escalation to 27 mg/m² was allowed at Cycle 3 or at subsequent cycles.","id":"BG004","title":"Carfilzomib - Dialysis"},{"description":"Total of all reporting groups","id":"BG005","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"26"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"24"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"5.70","value":"64.5"},{"groupId":"BG001","spread":"7.85","value":"63.5"},{"groupId":"BG002","spread":"9.65","value":"66.2"},{"groupId":"BG003","spread":"8.23","value":"73.0"},{"groupId":"BG004","spread":"7.91","value":"56.0"},{"groupId":"BG005","spread":"9.01","value":"64.6"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"22"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"28"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"11"}]}],"title":"African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"3"}]}],"title":"Asian/Pacific Islander"},{"categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"36"}]}],"title":"Caucasian"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"8"}]}],"title":"0 (Fully active)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"32"}]}],"title":"1 (Restrictive but ambulatory)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"10"}]}],"title":"2 (Ambulatory but unable to work)"}],"description":"Eastern Cooperative Oncology Group (ECOG) Performance Status is used by doctors and researchers to assess how a participants disease is progressing, assess how the disease affects the daily living activities of the participant and determine appropriate treatment and prognosis. 0 = Fully Active; 1 = Restricted activity but ambulatory; 2 = Ambulatory but unable to carry out work activities; 3 = Limited Self-Care; 4 = Completely Disabled, no self-care, confined to bed or chair; 5 = Dead.","paramType":"NUMBER","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","unitOfMeasure":"participants"}]}